Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating :

-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...

Related Keywords

United States , Janet Graesser , Jennifer Zibuda , Groupa Strep , Exchange Commission , Company Potential Pneumococcal Conjugate Vaccine , Corporate Communications , Nasdaq , Drug Administration , Sutro Biopharma Inc , Vaxcyte Inc , Data Monitoring Committee , Immunogenicity Data , Third Quarter , Provide Coverage , Coverage Against , Grant Pickering , Chief Executive Officer , Biologics License Application , Breakthrough Therapy , Sutro Biopharma , Private Securities Litigation Reform Act , Quarterly Report , Vice President , Senior Director , Investor Relations , Nasdaq Pcvx , Maxcyte , Nc ,